2009
Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.
Jiang E, Park E, Scharman C, Hsieh Y, Kadavallore A, Nguyen C, Zhao Y, McMillan M, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. Blood 2009, 114: 3072. DOI: 10.1182/blood.v114.22.3072.3072.Peer-Reviewed Original ResearchMedian survival timeAcute lymphoblastic leukemiaWhite blood cellsICG-001Control groupBlood cellsStandard chemotherapyRed blood cellsPeripheral bloodLymphoblastic leukemiaSmall molecule inhibitor ICG-001B-cell acute lymphoblastic leukemiaDrug resistanceCBP/β-cateninNormal hematopoiesisPromising therapeutic principleNormal white blood cellsConventional drug treatmentLeukemia cellsPrior intravenous injectionEnd of treatmentNovel therapeutic optionsNormal weight gainNew treatment modalitiesSubcutaneous osmotic pumps
2007
Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.
Kim Y, Park E, Lorentzen C, De La Torre B, Hsieh Y, Whang H, Klemm L, Nguyen C, McMillan M, Teo J, Muschen M, Kahn M. Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia. Blood 2007, 110: 1596. DOI: 10.1182/blood.v110.11.1596.1596.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaMedian survival timeStandard chemotherapyICG-001Expression of survivinLymphoblastic leukemiaLeukemia cellsXenograft modelDrug-resistant acute lymphoblastic leukemiaSmall molecule inhibitor ICG-001NOD/SCID xenograft modelHuman preCBP/β-cateninPromising therapeutic principleBlood count analysisSCID xenograft modelSurvival of miceNovel therapeutic optionsNew treatment modalitiesΒ-cateninDrug-resistant leukemia cellsΒ-catenin inhibitionHigh death rateResistant leukemia cellsSurvivin mRNA expression